In the TCGA data, which contained RNA-seq and clinical datasets from 374 HCC patients and 50 nontumor patients, ATAD2 mRNA expression was upregulated in the HCC samples compared to the nontumor samples (10.75 ± 0.05668 vs. 9.338 ± 0.06266; P < 0.0001, Figure 2). This evidence concerns the gene ATAD2 and hepatocellular carcinoma.